Synthetic lethality based combination approaches to ARID1A mutation in ovarian cancer
Description: Project Narrative The proposed research is relevant to public health because it will not only reveal critical molecular insights into the role of ARID1A mutation in cancer and particularly ovarian cancer, but also provide a scientific rationale for developing urgently needed new pre-clinical therapeutic strategies for this disease. These studies will also serve as a prototype for other epigenetic therapeutic strategies for cancers with genetic alterations in other regulators of chromatin structure, a well-recognized feature of many cancer types. Therefore, the proposed research is relevant to NIH’s mission in terms of developing fundamental knowledge that will reduce the burden of human illness.
Funder: National Cancer Institute
Funding type: research
Funder scheme: R01
Start date: 2019-07-18
End date: 2026-01-31
Investigator: RUGANG ZHANG
Institution: UNIVERSITY OF TX MD ANDERSON CAN CTR
Subfield: Molecular Biology
Domain: Life Sciences
Funded outputs count: 22
Funder award ID: R01CA239128
OpenAlex ID: G5192688857